Delivery Order SPE2DB24D2013-SPE2DB25FCJHY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xcopri 200 mg tablets (30-count units) on November 5, 2025, with a ceiling value of $1,206.27. This firm fixed-price delivery order, which is not set-aside, is to be completed by November 6, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 150 mg tablets (30-count units) under a firm fixed price contract valued at $1,393.98. This non-set-aside, competitively awarded delivery order has an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single line item procurement of this neurological...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets (30-count units) valued at $3,536.88. This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The contract has an ultimate completion date of August 11, 2025, and performance will be executed at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.44 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 50 mg tablets. The contract, issued on November 5, 2025, with completion scheduled for November 6, 2025, utilizes a firm fixed price structure with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order under its existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xcopri 200 mg tablets (30-count units) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed-price delivery order, valued at $1,768.44, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. The contract is issued as a child order under AmerisourceBergen's larger pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a $4,517.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 100 mg, with an ultimate completion date of November 3, 2025. This is a non-set-aside contract awarded competitively on October 31, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in Conshohocken, PA 19428. The delivery order is issued under...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJHYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Xcopri 200 mg tablets (30-count units) with a contract value of $1,012.37. This is a firm fixed-price delivery order with an ultimate completion date of June 6, 2025, representing a short-duration pharmaceutical supply transaction. The contract is non-competitive and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen fulfills critical supply requirements for military and veteran healthcare systems through this comprehensive global pharmaceutical support vehicle. Xcopri (cenobamate) is a seizure medication used in neurological treatment protocols, consistent with the company's portfolio of specialty medications and therapeutics delivered to Defense Health Agency and other government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 6/5/25 |